Inhibikase Therapeutics(US:IKT)2025-08-14 20:56Financial Performance - As of June 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $87.7 million, down from $97.5 million as of December 31, 2024[5]. - The net loss for the quarter ended June 30, 2025, was $9.9 million, or $0.11 per share, compared to a net loss of $5.0 million, or $0.66 per share for the same quarter in 2024[6]. - The company incurred a net loss of $23.6 million for the six months ended June 30, 2025, compared to a net loss of $9.6 million for the same period in 2024[6]. - The company’s total liabilities as of June 30, 2025, were $8.8 million, compared to $3.7 million as of December 31, 2024[14]. - The company’s accumulated deficit increased to $118.0 million as of June 30, 2025, from $94.4 million as of December 31, 2024[14]. Expenses - Research and development expenses for the quarter ended June 30, 2025, were $5.3 million, an increase from $3.1 million in the same quarter of 2024[7]. - Selling, general and administrative expenses for the quarter ended June 30, 2025, were $5.9 million, compared to $2.0 million for the same quarter in 2024[8]. Clinical Development - The company plans to initiate its Phase 2b clinical study of IKT-001 in PAH in the second half of 2025, with approximately 150 participants randomized to receive either 300 mg or 500 mg of IKT-001 or a placebo[4]. - The primary efficacy endpoint for the IMPROVE-PAH study is the change in pulmonary vascular resistance at Week 26[4]. - The company expects to maximize the efficacy of IKT-001 while minimizing gastrointestinal side effects, based on previous studies of imatinib[3].